Stock fact sheet · data as of
Neuronetics, Inc. (STIM): fair value, margin of safety and Wheel Score
Healthcare · Medical - Devices · United States · Speculative / Distressed
Is STIM undervalued?
At 1.89 (close of 16 Oct 2026), STIM has no GLS fair value: every one of the nine models needs a positive input (the company lost money over the last twelve months, EPS -0.43, it pays no dividend and its debts exceed what its assets would fetch), so the margin of safety is blank and the Wheel Score cannot be computed. Our screens leave the stock out at the first rule. What can be said from the nightly row is below.
The nightly engine files STIM under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for STIM
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | -0.7055 | -137% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 5.00 | +165% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Neuronetics, Inc. scores only 3 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 1.7/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC -34.6%, ROE -174.3%, ROA -27.6% - with debt at 4.04 times equity and negative free cash flow. Debt of 4.04 times equity is on the high side for the sector and is worth checking against the cash flow before treating the stock as a long-term hold.
Neuronetics, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Service 65%, Product 35% (quarter Q2 FY2026).
Institutional ownership scores 7/10, insider activity 10/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 3 / 9 | ROIC | -34.6% |
|---|---|---|---|
| GLS Moat | 1.7 / 10 | ROE | -174.3% |
| Debt / equity | 4.04 | ROA | -27.6% |
| Free-cash-flow yield | -7.0% | Payout ratio | 0% |
| Institutions | 7 / 10 | Insiders · Congress | 10 · 5 / 10 |
Wheel Score 38: Weak
With a Wheel Score of 38 Neuronetics, Inc. sits in the Weak band. The parts - Value 13/25, Health 7/20, Moat 3/15, Premium 5/20, Stability 12/20 - show where: Moat (3/15) scores lowest.
Implied volatility is 179%, far above the range the wheel strategy is built for. The premium looks generous; the Wheel Score gives it only 5 of 20 Premium points because moves of that size can blow through any strike. Chain open interest is 6,462 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 818k shares a day on a market cap of $144M, with a beta of 1.20; the Stability part of the Wheel Score gives that 12 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 13 / 25 | 0% margin of safety | |
| Health | 7 / 20 | Piotroski 3/9 | |
| Moat | 3 / 15 | moat 1.7/10 | |
| Premium | 5 / 20 | implied volatility 179% | |
| Stability | 12 / 20 | 818k shares/day, $144M cap, beta 1.20 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 3 Nov 2026 (before the open), 18 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Medical - Devices
The 12 companies below are the closest to Neuronetics, Inc. by market cap within the Medical - Devices industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| QTRX Quanterix Corporation | 3.06 | - | - | 37Weak | $145M |
| FOCL EDAP TMS S.A. American Depositary Shares | 4.13 | - | - | 43Weak | $155M |
| OWLT Owlet, Inc. | 4.44 | - | - | 40Weak | $130M |
| INGN Inogen, Inc. | 6.30 | - | - | 42Weak | $167M |
| RXST RxSight, Inc. | 4.52 | - | - | 43Weak | $188M |
| LUCD Lucid Diagnostics Inc. | 0.5201 | - | - | 36No options | $99M |
| ELMD Electromed, Inc. | 28.03 | 28.56 | +2% | 67Good | $232M |
| TLSI TriSalus Life Sciences, Inc. | 3.90 | - | - | 33Weak | $240M |
| PROF Profound Medical Corp. | 6.62 | - | - | 45Weak | $242M |
| SERA Sera Prognostics, Inc. | 2.07 | - | - | 32Weak | $80M |
| LUNG Pulmonx Corporation | 1.85 | - | - | 36Weak | $79M |
| TMCI Treace Medical Concepts, Inc. | 4.04 | - | - | 37Weak | $263M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about STIM
Is STIM undervalued right now?
The GLS models could not value STIM (the company lost money over the last twelve months, EPS -0.43, it pays no dividend and its debts exceed what its assets would fetch), so there is no fair value or margin of safety to compare the price of 1.89 against.
What is the Wheel Score of STIM and what does it mean?
STIM scores 38 out of 100 (Weak). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for STIM?
None of the nine GLS models produced a positive value for STIM (the company lost money over the last twelve months, EPS -0.43, it pays no dividend and its debts exceed what its assets would fetch), so there is no GLS fair value tonight.
When does Neuronetics, Inc. report earnings next?
The next earnings report is due on 3 Nov 2026 (before the open), 18 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does STIM have listed options, and how liquid are they?
Yes. The nightly snapshot found 70 listed contracts with 6,462 open interest across all expiries and implied volatility of 179% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.